Do serum neural autoantibodies signal immune reactivity but require symptom and CSF correlation?

Serum neural autoantibodies are vital biomarkers of autoimmune neurological disorders, yet their presence in peripheral blood does not always equate to active, pathogenic central nervous system disease.

Clinical evidence and diagnostic accuracy

• In clinical cohorts, serum-only autoantibody testing yields false-positive rates as high as 60%. Notably, 95% of these diagnostic false positives originate from relying solely on serum assays.
• Low-titer autoantibodies can be detected in healthy, asymptomatic individuals as a reflection of background autoimmunity, meaning serum positivity alone is insufficient to confirm an active disease process.
• Correlating antibody findings with objective neurological symptoms and paired cerebrospinal fluid (CSF) analyses drastically minimizes misdiagnosis and confirms true positives.

Compartmentalization and antibody dynamics

• The diagnostic sensitivity of neural autoantibodies depends heavily on the tested physiological compartment. For anti-NMDAR encephalitis, CSF analysis is highly specific and sensitive, whereas serum-only testing misses up to 15% of active, true-positive cases.
• Conversely, for specific cell-surface targets like LGI1 and Caspr2, serum testing demonstrates superior diagnostic sensitivity compared to CSF testing, highlighting the necessity of paired, multi-compartment evaluation.

Bottom line

• Serum neural autoantibodies signal immune reactivity, but clinical interpretation must be paired with clinical symptom correlation and, where appropriate, confirmatory CSF testing to ensure diagnostic accuracy.